[Retracted] Predictive Value of Serum Markers SFRP1 and CC16 in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Table 1
General clinical data of the study objects.
Items
Control (n = 60)
STCOPD (n = 65)
AECOPD (n = 58)
value
Age, years, mean (SD)
65.46 ± 8.53
63.13 ± 9.28
67.53 ± 8.29
0.023
Gender, male, (n, %)
49 (81.67)
52 (80.00)
51 (87.93)
0.474
BMI, kg/m2, mean (SD)
23.01 ± 2.27
22.81 ± 1.98
22.64 ± 2.11
0.638
History of smoking (n, %)
0.002
Yes
21 (35.00)
32 (49.23)
35 (60.34)
No
39 (65.00)
33 (50.77)
23 (39.66)
COPD duration, years, mean (SD)
NA
8.81 ± 2.41
10.23 ± 3.27
0.007
Lung function indexes, mean (SD)
FEV1 (% predicted)
98.54 ± 5.03
70.14 ± 11.38
62.33 ± 13.26
<0.001
FEV1/FVC (%)
83.29 ± 3.06
64.17 ± 5.34
57.87 ± 6.14
<0.001
CAT score, mean (SD)
NA
20.15 ± 3.58
27.78 ± 4.23
<0.001
Arterial blood gases, mean (SD)
PaO2 (mmHg)
83.69 ± 4.44
57.23 ± 6.36
56.11 ± 7.03
<0.001
PaCO2 (mmHg)
38.26 ± 5.31
43.09 ± 7.48
44.63 ± 6.52
<0.001
STCOPD, stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; CAT, the COPD assessment test.
